(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday reported positive results from trials of two cancer drugs, Enhertu and datopotamab deruxtecan. Read More
(Alliance News) - AstraZeneca PLC on Monday said its Andexxa phase four trial will be stopped early after achieving positive efficacy data. Read More
(Alliance News) - AstraZeneca PLC on Friday reported positive results from planned interim analysis of a phase three trial evaluating its Imfinzi drug in gastric and gastroesophageal junction cancers. Read More
(Alliance News) - AstraZeneca PLC on Thursday hailed another approval for cancer drug Lynparza, while it ceased its development programme for Crohn's disease-focused brazikumab. Read More
(Alliance News) - AstraZeneca PLC on Friday announced that its antibody complement inhibitor drug Ultomiris received another approval in Japan. Read More
(Alliance News) - AstraZeneca PLC on Friday said that its most recent trial testing Imfinzi showed that the therapy significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy. Read More
(Alliance News) - Stocks in London are expected to kick off the final trading day of a fraught week with a minor gain, though US debt ceiling uncertainty continues to temper sentiment. Read More
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Hires Chief Financial Officer Anna Manz of London Stock Exchange Group PLC as a non-executive director from September 1. Manz joined the price data, trading and clearing systems operator in November 2020 as CFO. She was CFO of speciality chemicals Johnson Matthey PLC from 2016 to 2020. Prior to that, Manz spent 17 years at London-based brewer and distiller Diageo PLC in a number of senior finance roles, Astra noted. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said its Tagrisso, used together with chemotherapy, showed improvement in progression-free survival for patients with lung cancer. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said the European Commission approved its drug Ultomiris in the EU for adults with autoimmune disease neuromyelitis optica spectrum disorder, known as NMOSD. Read More
(Alliance News) - The following London-listed shares received analyst recommendations xxxxday morning: Read More
(Alliance News) - AstraZeneca PLC on Tuesday said its Farxiga drug has been approved by the US Food & Drug Administration to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults. Read More
AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Non-Executive Chair Michel Demare buys 2,000 shares at GBP117.01, worth GBP234,020, on Friday last week. Read More
(Alliance News) - AstraZeneca PLC on Tuesday bemoaned the results of a regulatory meeting held by the US Food & Drug Administration, which suggested its Lynparza prostate cancer treatment should be limited to tumours with a BRCA mutation. Read More
(Alliance News) - AstraZeneca PLC on Friday said the US Food & Drug Administration's Oncologic Drugs Advisory Committee has recognised a favourable benefit risk profile for its Lynparza, plus abiraterone and prednisone or prednisolone, for the treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer. Read More
(Alliance News) - AstraZeneca PLC on Thursday said revenue decreased in the first quarter of the year as Covid-19 related sales dropped, but pretax profit surged. Read More
(Alliance News) - Stock prices in London opened lower on Thursday, with the FTSE 100 failing to get a boost by positive first-quarter results from major constituents including Barclays and AstraZeneca. Read More
(Alliance News) - Stocks in London were set to open lower on Thursday, as investors concern continued to mount about the health of the US banking sector after another largely lower finish in New York. Read More
(Alliance News) - European equities closed lower on Wednesday, with lingering banking sector worries hurting sentiment, while tech stocks outperformed wider markets in New York after well-received earnings overnight. Read More